JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA: A Case Report

  • 0From the Nuclear Medicine Research Center.
Clinical Nuclear Medicine +

|

February 2, 2024

|

February 2, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This case study details a patient with mixed neuroendocrine prostate cancer, showing resistance to quadruplet therapy. A modified treatment approach was used for the partially PSMA-negative metastatic prostate cancer.

Area Of Science

  • Oncology
  • Nuclear Medicine
  • Urology

Background

  • Metastatic prostate cancer (PC) poses significant treatment challenges, particularly mixed neuroendocrine PC (mNEPC).
  • Prostate-specific membrane antigen (PSMA) expression is a key factor in targeted radionuclide therapy.

Observation

  • A patient presented with de novo high-volume metastatic prostate cancer exhibiting heterogeneous PSMA expression (partially PSMA-negative).
  • Standard quadruplet therapy was initiated, but the partial PSMA negativity prompted a modified treatment strategy.

Findings

  • The modified protocol combined doublet hormonal therapy with 177Lu-PSMA and radiation therapy.
  • The patient showed an initial response, but disease recurrence was ultimately observed, underscoring treatment resistance.

Implications

  • This case highlights the resistant phenotype of mNEPC, even with advanced therapies.
  • Tailored treatment strategies are crucial for managing heterogeneous PSMA expression in metastatic prostate cancer.